These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27091885)

  • 1. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving "Zero" Defects for Visible Particles in Injectables.
    Johns J; Golfetto P; Bush T; Fantozzi G; Shabushnig J; Perry A; Degrazio F; Streich D; Miller J; Soukiassian H; Stanton A; Watson R
    PDA J Pharm Sci Technol; 2018; 72(6):640-650. PubMed ID: 30232141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Container Closure Integrity Testing-Practical Aspects and Approaches in the Pharmaceutical Industry.
    Brown H; Mahler HC; Mellman J; Nieto A; Wagner D; Schaar M; Mathaes R; Kossinna J; Schmitting F; Dreher S; Roehl H; Hemminger M; Wuchner K
    PDA J Pharm Sci Technol; 2017; 71(2):147-162. PubMed ID: 27789803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach.
    Langille SE
    PDA J Pharm Sci Technol; 2020; 74(3):359-366. PubMed ID: 31732691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection-Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility.
    Mazaheri M; Saggu M; Wuchner K; Koulov AV; Nikels F; Chalus P; Das TK; Cash PW; Finkler C; Levitskaya-Seaman SV; Case J; Parsons J; Gonzalez K
    J Pharm Sci; 2024 Mar; 113(3):616-624. PubMed ID: 37802369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development.
    Rauk AP; Griffiths KL; Gossage MD; Weiss WF
    J Pharm Sci; 2016 Nov; 105(11):3296-3303. PubMed ID: 27663382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

  • 11. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin, result and measurement of USP "essentially free" inspection for visible contaminating particles.
    Knapp JZ
    PDA J Pharm Sci Technol; 2000; 54(3):218-32. PubMed ID: 10927913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products.
    Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L
    J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The scientific basis for visible particle inspection.
    Knapp JZ
    PDA J Pharm Sci Technol; 1999; 53(6):291-302. PubMed ID: 10754727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Absolute" sterility and "absolute" freedom from particle contamination.
    Knapp JZ
    PDA J Pharm Sci Technol; 1998; 52(4):173-81. PubMed ID: 9752713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Physical Container Closure Integrity Test Methods and Artificial Leak Methodologies.
    Peláez SS; Mahler HC; Herdlitschka C; Wertli T; Kahl M; Koulov A; Matter A; Singh SK; Widmer M; Germershaus O; Mathaes R
    PDA J Pharm Sci Technol; 2019; 73(3):220-234. PubMed ID: 30651337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conducting Clinical Risk Assessments for Visible Particulate Matter in Parenteral Preparations.
    Ayres JD
    PDA J Pharm Sci Technol; 2018; 72(6):626-639. PubMed ID: 30158238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extractables Screening of Polypropylene Resins Used in Pharmaceutical Packaging for Safety Hazards.
    Jenke D
    PDA J Pharm Sci Technol; 2017; 71(5):346-367. PubMed ID: 28512176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.